Pathogenesis of the metabolic syndrome;Physiopathologie du syndrome métabolique

Annales de Dermatologie et de Venereologie

Volumn 135, Issue SUPPL. 4, 2008, Pages 243-248

  Jullien, D ^a  

^a University of Lyon   (France)

Author keywords

Adipokines; Adipose tissue; Insulin resistance; Obesity; Psoriasis

Indexed keywords

CARBOHYDRATE; LIPID; LEPTIN;

ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; ENVIRONMENTAL FACTOR; EPIGENETICS; HEREDITY; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; WORLD HEALTH ORGANIZATION; BIOLOGICAL MODEL; ENVIRONMENT; EXERCISE; GENETICS; HUMAN; HYPERTENSION; INFLAMMATION; NUTRITIONAL STATUS; PHYSIOLOGY; PSORIASIS; REVIEW;

ENVIRONMENT; EXERCISE; HUMANS; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LEPTIN; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; NUTRITIONAL STATUS; PSORIASIS;

EID: 48849104987     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(08)70542-8     Document Type: Article

References (58)

1. Alberti K.G., Zimmet P., and Shaw J. The metabolic syndrome--a new worldwide definition. Lancet 366 (2005) 1059-1062
2. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
3. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
4. Arner P. Genetic variance and lipolysis regulation: implications for obesity. Ann Med 33 (2001) 542-546
5. Hamid Y.H., Rose C.S., Urhammer S.A., Glumer C., Nolsoe R., Kristiansen O.P., et al. Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes. Diabetologia 48 (2005) 251-260
6. Bonadonna R.C., Del Prato S., Saccomani M.P., Bonora E., Gulli G., Ferrannini E., et al. Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes. J Clin Invest 92 (1993) 486-494
7. Gastaldelli A., Baldi S., Pettiti M., Toschi E., Camastra S., Natali A., et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 49 (2000) 1367-1373
8. Virtanen K.A., Iozzo P., Hallsten K., Huupponen R., Parkkola R., Janatuinen T., et al. Increased fat mass compensates for insulin resistance in abdominal obesity and type 2 diabetes: a positron-emitting tomography study. Diabetes 54 (2005) 2720-2726
9. Semenkovich C.F. Insulin resistance and atherosclerosis. J Clin Invest 116 (2006) 1813-1822
10. Steinberg H.O., and Baron A.D. Vascular function, insulin resistance and fatty acids. Diabetologia 45 (2002) 623-634
11. Taskinen M.R. Type 2 diabetes as a lipid disorder. Curr Mol Med 5 (2005) 297-308
12. Cooper S.A., Whaley-Connell A., Habibi J., Wei Y., Lastra G., Manrique C., et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 293 (2007) H2009-H2023
13. Reaven G.M. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 47 (2005) 201-210
14. Gastaldelli A., Sironi A.M., Ciociaro D., Positano V., Buzzigoli E., Giannessi D., et al. Visceral fat and beta cell function in non-diabetic humans. Diabetologia 48 (2005) 2090-2096
15. Despres J.P., and Lemieux I. Abdominal obesity and metabolic syndrome. Nature 444 (2006) 881-887
16. Montague C.T., and O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 49 (2000) 883-888
17. Bartness T.J., and Song C.K. Brain-adipose tissue neural crosstalk. Physiol Behav 91 (2007) 343-351
18. Jensen M.D. Is visceral fat involved in the pathogenesis of the metabolic syndrome? Human model. Obesity (Silver Spring) 14 Suppl 1 (2006) S20-S24
19. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett 580 (2006) 2917-2921
20. Van Gaal L.F., Mertens I.L., and De Block C.E. Mechanisms linking obesity with cardiovascular disease. Nature 444 (2006) 875-880
21. Kamei N., Tobe K., Suzuki R., Ohsugi M., Watanabe T., Kubota N., et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 281 (2006) 26602-26614
22. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., and Ferrante Jr. A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112 (2003) 1796-1808
23. Tilg H., and Moschen A.R. Adipocytokines:mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6 (2006) 772-783
24. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., and Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95 (1995) 2409-2415
25. Hotamisligil G.S., Shargill N.S., and Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993) 87-91
26. Shoelson S.E., Lee J., and Goldfine A.B. Inflammation and insulin resistance. J Clin Invest 116 (2006) 1793-1801
27. Porter M.H., Cutchins A., Fine J.B., Bai Y., and DiGirolamo M. Effects of TNF-alpha on glucose metabolism and lipolysis in adipose tissue and isolated fat-cell preparations. J Lab Clin Med 139 (2002) 140-146
28. Hutley L., and Prins J.B. Fat as an endocrine organ:relationship to the metabolic syndrome. Am J Med Sci 330 (2005) 280-289
29. Correia M.L., and Rahmouni K. Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabetes Obes Metab 8 (2006) 603-610
30. Matarese G., Moschos S., and Mantzoros C.S. Leptin in immunology. J Immunol 174 (2005) 3137-3142
31. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., and Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116 (2006) 1784-1792
32. Tsatsanis C., Zacharioudaki V., Androulidaki A., Dermitzaki E., Charalampopoulos I., Minas V., et al. Peripheral factors in the metabolic syndrome:the pivotal role of adiponectin. Ann N Y Acad Sci 1083 (2006) 185-195
33. Bokarewa M., Nagaev I., Dahlberg L., Smith U., and Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 174 (2005) 5789-5795
34. Steppan C.M., and Lazar M.A. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab 13 (2002) 18-23
35. Yang Q., Graham T.E., Mody N., Preitner F., Peroni O.D., Zabolotny J.M., et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436 (2005) 356-362
36. Shimomura I., Funahashi T., Takahashi M., Maeda K., Kotani K., Nakamura T., et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 2 (1996) 800-803
37. Pickup J.C. Inflammatory markers and type 2 diabetes. Diabetes Technol Ther 8 (2006) 1-6
38. Pickup J.C., Mattock M.B., Chusney G.D., and Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40 (1997) 1286-1292
39. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 444 (2006) 860-867
40. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., and Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116 (2006) 3015-3025
41. Ozcan U., Cao Q., Yilmaz E., Lee A.H., Iwakoshi N.N., Ozdelen E., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306 (2004) 457-461
42. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114 (2004) 1752-1761
43. Summers S.A. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 45 (2006) 42-72
44. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., et al. A central role for JNK in obesity and insulin resistance. Nature 420 (2002) 333-336
45. Shoelson S.E., Lee J., and Yuan M. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity-and diet-induced insulin resistance. Int J Obes Relat Metab Disord 27 Suppl 3 (2003) S49-52
46. Houstis N., Rosen E.D., and Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440 (2006) 944-948
47. Perreault M., and Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 7 (2001) 1138-1143
48. Rui L., Yuan M., Frantz D., Shoelson S., and White M.F. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277 (2002) 42394-42398
49. Kanda H., Tateya S., Tamori Y., Kotani K., Hiasa K., Kitazawa R., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116 (2006) 1494-1505
50. Weisberg S.P., Hunter D., Huber R., Lemieux J., Slaymaker S., Vaddi K., et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116 (2006) 115-124
51. Dandona P., Aljada A., and Mohanty P. The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 45 (2002) 924-930
52. Hansson G.K., Robertson A.K., and Soderberg-Naucler C. Inflammation and atherosclerosis. Annu Rev Pathol 1 (2006) 297-329
53. Gisondi P., Tessari G., Conti A., Piaserico S., Schianchi S., Peserico A., et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 157 (2007) 68-73
54. Sommer D.M., Jenisch S., Suchan M., Christophers E., and Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 298 (2006) 321-328
55. Sterry W., Strober B.E., and Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 157 (2007) 649-655
56. Hamminga E.A., van der Lely A.J., Neumann H.A., and Thio H.B. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses 67 (2006) 768-773
57. Dandona P., Aljada A., and Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25 (2004) 4-7
58. Fernandez-Real J.M., and Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24 (2003) 278-301